A

Neoantigen Targetability in Progressive Advanced Melanoma

Clinical Cancer Research, vol. 29, pp. 4278–4288

Abstract

PURPOSE: The availability of (neo)antigens and the infiltration of tumors by (neo)antigen-specific T cells are crucial factors in cancer immunotherapy. In this study, we aimed to investigate the targetability of (neo)antigens in advanced progessive melanoma and explore the potential for continued T-cell-based immunotherapy. EXPERIMENTAL DESIGN: We examined a cohort of eight patients with melanoma who had sequential metastases resected at early and later time points. Antigen-presenting capacity was assessed using IHC and flow cytometry. T-cell infiltration was quantified through multiplex immunofluorescence. Whole-exome and RNA sequencing were conducted to identify neoantigens and assess the expression of neoantigens and tumor-associated antigens. Mass spectrometry was used to evaluate antigen presentation. Tumor recognition by autologous T cells was assessed by coculture assays with cell lines derived from the metastatic lesions. RESULTS: We observed similar T-cell infiltration in paired early and later metastatic (LM) lesions. Although elements of the antigen-presenting machinery were affected in some LM lesions, both the early and later metastasis-derived cell lines were recognized by autologous T cells. At the genomic level, the (neo)antigen landscape was dynamic, but the (neo)antigen load was stable between paired lesions. CONCLUSIONS: Our findings indicate that subsequently isolated tumors from patients with late-stage melanoma retain sufficient antigen-presenting capacity, T-cell infiltration, and a stable (neo)antigen load, allowing recognition of tumor cells by T cells. This indicates a continuous availability of T-cell targets in metastases occurring at different time points and supports further exploration of (neo)antigen-specific T-cell-based therapeutic approaches for advanced melanoma.

Authors 18

  1. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  2. Leiden University Medical Center

    Affiliation as printed

    2Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands

  3. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  4. Leiden University Medical Center

    Affiliation as printed

    2Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands

  5. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  6. Leiden University Medical Center

    Affiliation as printed

    3Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands

  7. Leiden University Medical Center

    Affiliation as printed

    3Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands

  8. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  9. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  10. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  11. Leiden University Medical Center

    Affiliation as printed

    2Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands

  12. Leiden University Medical Center

    Affiliation as printed

    2Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands

  13. Leiden University Medical Center

    Affiliation as printed

    3Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands

  14. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  15. Leiden University Medical Center

    Affiliation as printed

    4Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands

  16. Leiden University Medical Center

    Affiliation as printed

    3Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands

  17. Leiden University Medical Center

    Affiliation as printed

    1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

  18. Leiden University Medical Center

    Affiliation as printed

    2Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands

Cited by 0 stored of 0

No patents citing this paper on Lens.org (checked 2026-10-11).

References 50